Illumina is trading 5.25% down at $225.71; available reporting identified no clear company-specific catalyst for the November 4 decline. - The Singapore SG-INSIGHT sequencing selection was announced before the decline; coverage linked it to Illumina’s 5.1% rise in the prior session, not today’s drop. - Biotech shares and the broader market were reported higher, so the available evidence does not establish why Illumina fell.